Nebivolol

立即咨询

Nebivolol

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

118457-14-0

包装与价格：

包装	价格(元)
100mg	电议
250mg	电议
500mg	电议

产品名称

奈必洛尔
R 065824

产品介绍

Nebivolol (R 065824) 是一种 β 受体阻滞剂，具有口服活性和高 β (1)-受体亲和力。Nebivolol 具有直接的血管扩张剂特性和肾上腺素能阻断特性。Nebivolol 可用于高血压、冠状动脉疾病、充血性心力衰竭和缺血性心脏病等多种疾病的研究。

生物活性

Nebivolol (R 065824) is an orally activebeta receptorblocker and has the high beta(1)-receptor affinity. Nebivolol has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease^[1]^[2].

体外研究
(In Vitro)

Nebivolol improves endothelial dysfunction via its strong stimulatory effects on the activity of the endothelial nitric oxide synthase and via its antioxidative properties^[1].
Nebivolol (0.1 μM-10 μM, 1, 2, 4, 7 or 14 days) inhibits haCSMC or haEC proliferation with IC₅₀values of ~ 6.0 μM^[2].
Nebivolol (0.1 μM-10 μM, 24 h) induces a moderate rate of apoptosis^[2].
Nebivolol (0.1, 1, 5,10 μM, 4 days)increases NO formation and decreases endothelin-1 secretion in HaCEs^[2]

Cell Proliferation Assay^[2]

Cell Line:	haCSMCs (human coronary smooth muscle cells) and haECs (endothelial cells)
Concentration:	0.1 μM-10 μM
Incubation Time:	1, 2, 4, 7 or 14 days
Result:	Reduced proliferation in HaECs and HaCSMCs in a concentration- and time-dependent.

Apoptosis Analysis^[2]

Cell Line:	haCSMCs and haECs
Concentration:	0.1 μM-10 μM
Incubation Time:	24 h
Result:	Induced a moderate apoptosis in concentration-dependent and showed a decrease of haCSMCs in the S-phase by 66%.

Clinical Trial

分子量

405.44

Formula

C₂₂H₂₅F₂NO₄

CAS 号

118457-14-0

中文名称

奈必洛尔

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.